[en] Pasireotide (SOM230), a multireceptor-targeted somatostatin analogue, has exhibited favorable safety/tolerability in several clinical studies. A long-acting-release (LAR) formulation of pasireotide may offer advantages over the subcutaneous formulation. This randomized, open-label, Phase I study evaluated the safety, PK, and PD of pasireotide LAR 20, 40, or 60 mg/month in patients with acromegaly. Safety assessments and blood samples for PK and PD were taken at designated time points. Thirty-five patients were randomized and completed the study. Steady-state pasireotide concentrations were achieved following three monthly injections. Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group). At study end, 51% and 57% of patients achieved GH levels </=2.5 mug/L and IGF-1 levels below ULN, respectively. Compared with baseline, fasting blood glucose and HbA1c levels increased, whereas fasting blood insulin levels decreased. Acromegaly symptoms were generally improved. Adverse events were mostly gastrointestinal and mild/moderate. Pasireotide LAR was generally well tolerated. Steady-state PK was achieved after three monthly doses; exposures were approximately dose proportional. Control of GH, IGF-1, and symptoms improved, suggesting that pasireotide LAR may be an effective treatment for acromegaly.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Petersenn, Stephan
Bollerslev, Jens
Arafat, Ayman M.
Schopohl, Jochen
Serri, Omar
Katznelson, Laurence
Lasher, Janet
Hughes, Gareth
Hu, Ke
Shen, George
Resendiz, Karina Hermosillo
Giannone, Vanessa
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Melmed S,. Medical progress: acromegaly. N Engl J Med. 2006; 355: 2558-2573.
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94: 1509-1517.
Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G,. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002; 146: 707-716.
Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012; 366: 914-924.
Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine. 2012; 42: 366-374.
Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012; 6: 71-79.
Petersenn S, Hu K, Maldonado M, et al. Tolerability and dose-proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin Ther. 2012; 34: 677-688.
Lin TH, Hu K, Flarakos J, et al. Assessment of the absorption, metabolism and excretion of [(1)(4)C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol. 2013; 72: 181-188.
Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab. 2010; 95: 2781-2789.
Dietrich H, Hu K, Ruffin M, et al. Safety, tolerability and pharmacokinetics of a single dose of pasireotide long-acting release (LAR) in healthy volunteers: a single-center Phase I study. Eur J Endocrinol. 2012; 166: 821-828.
National Cancer Institute,. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf; 2006.
Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013; 72: 387-395.
Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study. Endocr Relat Cancer. 2012; 19: 657-666.
Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014; 99: 791-799.
Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009; 94: 115-122.
Petersenn S, Unger N, Hu K, et al. Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol. 2012; 52: 1017-1027.
Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S,. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013; 98: 3446-3453.
Breitschaft A, Hu K, Hermosillo RK, Darstein C, Golor G,. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014; 103: 458-465.
